Krensavage Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Krensavage Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-855,860	Closed	-$18.4M	–	21
2025 Q4	$18.4M	Sell	855,860 -100,000	-10%	-$1.94M	6.51%	6
2025 Q3	$14.6M	Sell	955,860 -3,017	-0.3%	-$39.3K	6.22%	8
2025 Q2	$8.49M	Buy	958,877 +8,877	+0.9%	+$78K	4.49%	9
2025 Q1	$7.44M	Buy	+950,000	New	+$7.96M	4.11%	11

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Krensavage Asset Management's AVDL Position: Q1 2026 in Review

Krensavage Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 855,860 shares — an estimated $18.4M sold.

Krensavage Asset Management first reported a position in AVDL in Q1 2025 and held it in 4 quarters. The position peaked at $18.4M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Krensavage Asset Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Krensavage Asset Management sold 855,860 Avadel Pharmaceuticals shares in Q1 2026, an estimated $18.4M.
Krensavage Asset Management first reported a position in Avadel Pharmaceuticals in Q1 2025 and held it in 4 quarters.
Krensavage Asset Management's Avadel Pharmaceuticals position peaked at $18.4M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Krensavage Asset Management's 13F filing for Q1 2026, filed 15 May 2026.